NCT06287463 - Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

May 14, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions

Advanced Solid TumorRAF MutationRAS MutationNF1 MutationNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaMelanomaBRAF Gene MutationCRAF Gene MutationCastration-Resistant Prostate Cancer (CRPC)

Interventions

DRUG

DCC-3084

Administered orally

Trial Locations (9)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

22031

NEXT Oncology Virginia, Fairfax

32827

SCRI Florida Cancer Specialists, Orlando

37203

SCRI Oncology Partners, Nashville

78229

NEXT Oncology, San Antonio

80218

SCRI HealthONE, Denver

90033

University of Southern California - Norris Comprehensive Cancer Center, Los Angeles

94158

University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco

02215

Dana-Farber Cancer Institute, Boston